CN1298290A - 视黄酸活性抑制剂在减缓脱发中的应用 - Google Patents
视黄酸活性抑制剂在减缓脱发中的应用 Download PDFInfo
- Publication number
- CN1298290A CN1298290A CN99804411A CN99804411A CN1298290A CN 1298290 A CN1298290 A CN 1298290A CN 99804411 A CN99804411 A CN 99804411A CN 99804411 A CN99804411 A CN 99804411A CN 1298290 A CN1298290 A CN 1298290A
- Authority
- CN
- China
- Prior art keywords
- benzoic acid
- tretinoin
- activity inhibitor
- slow down
- tetramethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 title claims abstract description 50
- 239000003112 inhibitor Substances 0.000 title claims abstract description 41
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 18
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 title claims description 53
- 229960001727 tretinoin Drugs 0.000 title claims description 50
- 230000003676 hair loss Effects 0.000 title abstract 2
- 229930002330 retinoic acid Natural products 0.000 title description 5
- 208000024963 hair loss Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 46
- 210000004209 hair Anatomy 0.000 claims abstract description 32
- 239000002537 cosmetic Substances 0.000 claims abstract description 10
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 52
- 239000005711 Benzoic acid Substances 0.000 claims description 27
- 235000010233 benzoic acid Nutrition 0.000 claims description 27
- 231100000360 alopecia Toxicity 0.000 claims description 15
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 12
- 230000003779 hair growth Effects 0.000 claims description 11
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 6
- 229960004889 salicylic acid Drugs 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 229960003512 nicotinic acid Drugs 0.000 claims description 5
- 235000001968 nicotinic acid Nutrition 0.000 claims description 5
- 239000011664 nicotinic acid Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000003672 processing method Methods 0.000 claims description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 125000005605 benzo group Chemical group 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 18
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 239000005557 antagonist Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- -1 formamido Chemical group 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 8
- 230000000284 resting effect Effects 0.000 description 8
- 150000004492 retinoid derivatives Chemical class 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 229940096885 Retinoic acid receptor agonist Drugs 0.000 description 6
- 102000003702 retinoic acid receptors Human genes 0.000 description 6
- 108090000064 retinoic acid receptors Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000003780 hair follicle Anatomy 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000003778 catagen phase Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000222065 Lycoperdon Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 102000001938 Plasminogen Activators Human genes 0.000 description 2
- 108010001014 Plasminogen Activators Proteins 0.000 description 2
- 241000768494 Polymorphum Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000013066 combination product Substances 0.000 description 2
- 229940127555 combination product Drugs 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229940127126 plasminogen activator Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- OQZGLXOADHKTDN-UHFFFAOYSA-N 1-oxidopyrimidin-1-ium Chemical compound [O-][N+]1=CC=CN=C1 OQZGLXOADHKTDN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- WLOMWJGRCLMZPW-UHFFFAOYSA-N 2-hydroxybenzoic acid;propane-1,2-diol Chemical compound CC(O)CO.OC(=O)C1=CC=CC=C1O WLOMWJGRCLMZPW-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- FCJJVDFZQOZKQD-UHFFFAOYSA-N C(C)C#C.C1=CC=CC2=CC=CC=C12 Chemical group C(C)C#C.C1=CC=CC2=CC=CC=C12 FCJJVDFZQOZKQD-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 101000883061 Chassalia parviflora Circulin-D Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 description 1
- 102100033909 Retinoic acid receptor beta Human genes 0.000 description 1
- 102100033912 Retinoic acid receptor gamma Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JATXLCWZFQHYGQ-UHFFFAOYSA-N benzoic acid;propane-1,2-diol Chemical compound CC(O)CO.OC(=O)C1=CC=CC=C1 JATXLCWZFQHYGQ-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000003648 hair appearance Effects 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 201000006122 hypervitaminosis A Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 1
- 108091008726 retinoic acid receptors α Proteins 0.000 description 1
- 108091008761 retinoic acid receptors β Proteins 0.000 description 1
- 108091008760 retinoic acid receptors γ Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
- A61Q7/02—Preparations for inhibiting or slowing hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR98/03978 | 1998-03-31 | ||
| FR9803978A FR2776511B1 (fr) | 1998-03-31 | 1998-03-31 | Utilisation dans ou pour la preparation d'une composition d'au moins un inhibiteur de l'activite de l'acide retinoique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1298290A true CN1298290A (zh) | 2001-06-06 |
Family
ID=9524693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99804411A Pending CN1298290A (zh) | 1998-03-31 | 1999-03-24 | 视黄酸活性抑制剂在减缓脱发中的应用 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1066017A1 (fr) |
| JP (1) | JP2002509870A (fr) |
| KR (1) | KR20010042104A (fr) |
| CN (1) | CN1298290A (fr) |
| AR (1) | AR015551A1 (fr) |
| AU (1) | AU2938899A (fr) |
| BR (1) | BR9908411A (fr) |
| CA (1) | CA2324899A1 (fr) |
| FR (1) | FR2776511B1 (fr) |
| HU (1) | HUP0102411A3 (fr) |
| IL (1) | IL137859A0 (fr) |
| NO (1) | NO20004880L (fr) |
| PL (1) | PL343004A1 (fr) |
| RU (1) | RU2193877C2 (fr) |
| WO (1) | WO1999049838A1 (fr) |
| ZA (1) | ZA200004483B (fr) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2733684B1 (fr) * | 1995-05-03 | 1997-05-30 | Cird Galderma | Utilisation de retinoides dans une composition cosmetique ou pour la fabrication d'une composition pharmaceutique |
| FR2739777B1 (fr) * | 1995-10-11 | 1997-11-14 | Cird Galderma | Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose |
| US5965606A (en) * | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
| HUP9902645A3 (en) * | 1996-03-18 | 1999-12-28 | Eisai Co Ltd | Fused-ring carboxylic acid derivatives |
-
1998
- 1998-03-31 FR FR9803978A patent/FR2776511B1/fr not_active Expired - Fee Related
-
1999
- 1999-03-24 KR KR1020007010470A patent/KR20010042104A/ko not_active Application Discontinuation
- 1999-03-24 IL IL13785999A patent/IL137859A0/xx unknown
- 1999-03-24 BR BR9908411-2A patent/BR9908411A/pt not_active IP Right Cessation
- 1999-03-24 RU RU2000127111/14A patent/RU2193877C2/ru active
- 1999-03-24 PL PL99343004A patent/PL343004A1/xx not_active Application Discontinuation
- 1999-03-24 JP JP2000540805A patent/JP2002509870A/ja active Pending
- 1999-03-24 WO PCT/FR1999/000687 patent/WO1999049838A1/fr not_active Application Discontinuation
- 1999-03-24 HU HU0102411A patent/HUP0102411A3/hu unknown
- 1999-03-24 CN CN99804411A patent/CN1298290A/zh active Pending
- 1999-03-24 EP EP99910423A patent/EP1066017A1/fr not_active Withdrawn
- 1999-03-24 CA CA002324899A patent/CA2324899A1/fr not_active Abandoned
- 1999-03-24 AU AU29388/99A patent/AU2938899A/en not_active Abandoned
- 1999-03-30 AR ARP990101412A patent/AR015551A1/es unknown
-
2000
- 2000-08-29 ZA ZA200004483A patent/ZA200004483B/en unknown
- 2000-09-28 NO NO20004880A patent/NO20004880L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999049838A1 (fr) | 1999-10-07 |
| HUP0102411A3 (en) | 2002-12-28 |
| FR2776511B1 (fr) | 2001-05-11 |
| AU2938899A (en) | 1999-10-18 |
| PL343004A1 (en) | 2001-07-30 |
| ZA200004483B (en) | 2002-02-27 |
| EP1066017A1 (fr) | 2001-01-10 |
| HUP0102411A2 (hu) | 2001-11-28 |
| NO20004880D0 (no) | 2000-09-28 |
| NO20004880L (no) | 2000-11-30 |
| CA2324899A1 (fr) | 1999-10-07 |
| FR2776511A1 (fr) | 1999-10-01 |
| JP2002509870A (ja) | 2002-04-02 |
| BR9908411A (pt) | 2000-12-05 |
| IL137859A0 (en) | 2001-10-31 |
| AR015551A1 (es) | 2001-05-02 |
| RU2193877C2 (ru) | 2002-12-10 |
| KR20010042104A (ko) | 2001-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1051704C (zh) | 含视黄酸和生育酚的组合物 | |
| US5514672A (en) | Use of retinoids and compositions containing same for hair growth | |
| CN1045160C (zh) | 毛发生长修饰剂 | |
| WO2008036238A2 (fr) | Utilisation de modulateurs lxr dans la prévention et le traitement du vieillissement cutané | |
| JP2006131633A (ja) | 皮膚の老化の徴候を抑制する尿素化合物の使用 | |
| MXPA03007609A (es) | Uso de inhibidores egfr naturales para evitar efectos secundarios debidos a terapia de retinoide, jabones y otros estimulos que activan el receptor del factor de crecimiento epidermico. | |
| JP2000226317A (ja) | 毛髪保護作用と毛髪減損の予防性並びにアンドロゲン性脱毛症の外因作用とその結果もたらされる毛髪減損の低下性において、改善された性質を有するヘアロ―ション | |
| CN1505498A (zh) | 毛发和/或头皮用组合物 | |
| NO334680B1 (no) | Sammensetninger som topisk formulering for anvendelse i håret inneholdende melatonin, gingko biloba og biotin samt anvendelse derav. | |
| CN1993102A (zh) | 包含脒和烷烃多元醇的组合物 | |
| FR2717381A1 (fr) | Compositions à base d'alpha-pyrones pour induire et stimuler la croissance des cheveux et/ou freiner leur chute et utilisation. | |
| CN1816316A (zh) | 用作自晒黑组合物的包含水溶性维生素B3化合物和α－羟基羰基自晒黑剂的化妆品组合物 | |
| US11083683B2 (en) | Topical composition | |
| Kim et al. | Clinical evaluation of a new-formula shampoo for scalp seborrheic dermatitis containing extract of Rosa centifolia petals and epigallocatechin gallate: a randomized, double-blind, controlled study | |
| CN1795926A (zh) | 治疗皮肤症状的方法 | |
| CN1625384A (zh) | 用于治疗痤疮的局部用氨苯砜 | |
| AU707390B2 (en) | Use of inhibitors of the activity of retinoic acid to promote healing | |
| CN1503655A (zh) | 糖摄取促进剂 | |
| AU2015261537A1 (en) | Association of a tetrapeptide and a glyceryl ester for treating androgenic alopecia | |
| CN1853608A (zh) | 化妆品或皮肤病学组合物 | |
| CN1218663A (zh) | 在化妆和药物制剂中稳定维生素a和/或维生素a衍生物的2'-磷酸抗坏血酸酯的使用 | |
| CN1889919A (zh) | Ppar受体活化剂在化妆品和皮肤病学中的用途 | |
| CN1298290A (zh) | 视黄酸活性抑制剂在减缓脱发中的应用 | |
| CN1917878A (zh) | 刺激毛发生长的方法 | |
| EP0749755A2 (fr) | Procédé pour identifier des composés antagonistes des récepteurs RARs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |